Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson Disease
Interventions
ursodeoxycholic acid
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Kybella With Triamcinolone

NCT03361176
Conditions
Adiposity
Interventions
Injectable sodium deoxycholate, Injectable sodium deoxycholate with Triamcinolone acetate
Drug · Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Hunt Valley, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Injection Comfort of Two Formulations of ATX-101

NCT01320761
Conditions
Healthy
Interventions
ATX-101-BA-free, ATX-101-BA
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Omaha, Nebraska • Plano, Texas
Terminated Phase 2Phase 3 Interventional Results available

Trial of High-dose Urso in Primary Sclerosing Cholangitis

NCT00059202
Conditions
Primary Sclerosing Cholangitis
Interventions
Ursodeoxycholic Acid, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Conditions
Colorectal Cancer
Interventions
Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat

NCT04054011
Conditions
Adiposity
Interventions
Deoxycholic Acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Conditions
Infection, Pulmonary Complications
Interventions
amphotericin B deoxycholate, voriconazole
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Wethersfield, Connecticut
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

NCT04640571
Conditions
Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions
pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Brassiere Strap Fat (BSF), Bra Strap Fat (BSF)
Interventions
Deoxycholic Acid
Drug
Lead sponsor
Juva Skin & Laser Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Primary Sclerosing Cholangitis
Interventions
ursodeoxycholic acid (UDCA)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
5 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Completed Not applicable Interventional Accepts healthy volunteers

Infant Fecal Insult Study

NCT02979210
Conditions
Dermatitis
Interventions
Artificial Fecal Insult, Phosphate Buffered Saline
Other
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Irving, Texas
Terminated Not applicable Interventional Accepts healthy volunteers

Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat

NCT03284034
Conditions
Upper Back Fat
Interventions
CoolCurve, ATX-101
Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Neurofibromatosis 1
Interventions
Kybella, Asclera
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

NCT01632917
Conditions
Healthy
Interventions
ATX-101 - U.S., ATX-101 - EU
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02163902
Conditions
Submental Fat, Healthy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
San Diego, California • Englewood, Colorado • Coral Gables, Florida + 9 more
Conditions
Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
amphotericin B deoxycholate, nystatin
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
Conditions
Facial Contouring
Interventions
OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System, SkinMedica Products, KYBELLA
Drug · Device · Other
Lead sponsor
AbbVie
Industry
Eligibility
22 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Redondo Beach, California • Vista, California • Washington D.C., District of Columbia + 7 more
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
EZ-Urso combination therapy
Drug
Lead sponsor
Gregory Graf, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Submental Study (Sequential Treatment Approach)

NCT03510598
Conditions
Body Fat Disorder
Interventions
The ZELTIQ CoolSculpting System, Kybella 20 MG in 2 ML Injection
Device · Drug
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Ulcerative Colitis, Pouchitis
Interventions
ursodiol (ursodeoxycholic acid, UDCA)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
18
States / cities
Beverly Hills, California • La Jolla, California • San Juan Capistrano, California + 13 more
Conditions
Liver Cirrhosis, Biliary
Interventions
INT-747, Ursodeoxycholic Acid (URSO), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more
Withdrawn Not applicable Interventional

Cholestanol in Humans

NCT00018694
Conditions
Cerebrotendinous Xanthomatosis
Interventions
Chenodeoxycholic Acid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
5 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
East Orange, New Jersey